Announcement

Senhwa announces the first patient dosed in thephase II study of CX-4945 with Community-AcquiredPneumonia associated with viral infection in Taiwan.

Download

Mar: 20; 2024

Due to strategy adjustment, the Company decidesto early terminate the Phase II study of Silmitasertibto treat hospitalized patients with COVID-19.

Download

Jan: 05; 2024

Yuanta Analyst Research Report of Senhwa Biosciences, Inc.

Download

Dec: 26; 2019

Senhwa Biosciences Silmitasertib / Basal Cell Carcinoma Trial Completed 1st Patient Enrollment

Download

Apr: 17; 2019

Senhwa Biosciences Silmitasertib filed IND of Medulloblastoma approved by FDA

Download

Jan: 06; 2019

The Company will be invited to present on a 2-days roadshow :「2018 Taiwan CEO Day」 in Singapore and Hong Kong on 25 and 26 August, 2018

1. Date: 08/25~26, 2018 2. Time: 09:00 3. Venue: Singapore/Hong Kong 4. Info: Presentation file as attached

Oct: 22; 2018

The Company will be invited by Yuanta Securities to present on 20 April, 2018

1. Date: 04/20, 2018 2. Time: 15:30 3. Venue: Taipei, Taiwan 4. Info: Presentation file as attached

Apr: 18; 2018

The Company will be invited to present on a 2-days roadshow :「2018 Taiwan CEO Day」 in Hong Kong from 12 April, 2018

1. Date: 04/12~13, 2018 2. Time: 09:00 3. Venue: Hong Kong 4. Info: Presentation file as attached

Apr: 09; 2018

The Company will launch a two-day non-deal roadshow (NDR) in San Francisco USA from Jan 26 , 2018

• The Company will launch a 2-day non-deal roadshow (NDR) in San Francisco starting from 26 Jan 2018, and the presentation file as attached.

Jan: 25; 2018

The Company will launch a three-day non-deal roadshow (NDR) in Singapore and Hong Kong starting from December 11 , 2017

The Company will launch a three-day non-deal roadshow (NDR) in Singapore and Hong Kong starting from December 11 , 2017 and presentation files as attached.

Dec: 08; 2017

Investor Relations